Spexis (SPEX)

Executive Summary

Spexis AG (formerly Polyphor) is a Swiss clinical-stage biopharmaceutical company specializing in macrocyclic molecules for rare diseases and cancer, with a focus on antibiotic-resistant infections and oncology. Leveraging its proprietary macrocycle and OMPTA platforms, the company targets challenging drug structures. Its most advanced asset is an inhaled therapy for cystic fibrosis (CF) that has already received marketing authorization in Europe, providing a commercial foundation. Beyond CF, Spexis is developing a pipeline of novel macrocyclic antibiotics and oncology candidates, including POL7080 for ventilator-associated pneumonia and POL6326 for cancer, which have shown promise in early-stage trials. The company’s strategy centers on clinical validation of its platform and expansion of its approved product into new geographies and indications. Looking ahead, Spexis is positioned to execute on several near-term value drivers. The approved CF therapy presents opportunities for market share growth in Europe and potential label expansion. Meanwhile, key clinical readouts from the antibiotic and oncology programs are expected within the next 12–18 months, which could significantly de-risk the platform. Partnerships or licensing deals for the pipeline assets remain a catalyst for non-dilutive funding and validation. With a focused strategy and a commercial product generating revenue, Spexis offers a balanced risk/reward profile for investors seeking exposure to novel macrocyclic therapeutics in infectious disease and oncology.

Upcoming Catalysts (preview)

• Q4 2026Market expansion and label update for approved CF therapy in Europe70% success
• Q3 2026Phase II data readout for lead antibiotic candidate (POL7080) in resistant infections50% success
• Q2 2026Partnership or licensing agreement for oncology pipeline (e.g., POL6326)40% success